SCHEMBL6315872

SCHEMBL6315872

Cn1c(=O)c2nc(C(=O)c3ccccc3)c(-c3ccccc3)nc2n(C)c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
ALDH1A1 P00352 7/20 0.63
GAA P10253 3/20 0.63
GLA P06280 2/20 0.63
HPGD P15428 1/20 0.63
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
USP2 O75604 1/20 0.54
RECQL P46063 1/20 0.54
ADORA2B P29275 4/20 0.48
ADORA2A P29274 2/20 0.48
HSD17B10 Q99714 3/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
CYP1A2 P05177 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA1 P30542 1/20 0.43
BLM P54132 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437101 0.90 ALDH1A1 (0.52) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL7526429 0.82 KDM4E (0.78) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL5441255 0.80 KDM4E (0.71) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL5447101 0.78 KDM4E (0.67) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL5452939 0.75 KDM4E (0.89) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL6314617 0.75 KDM4E (0.67) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL7524591 0.74 ALDH1A1 (0.56) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL6316654 0.74 ALDH1A1 (0.65) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL6314769 0.73 ALDH1A1 (0.64) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL14132949 0.71 KDM4E (0.61) KDM4EALDH1A1GAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US claimed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US claimed
US-6946465-B2 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2005-09-20 US disclosed
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2003-12-25 US disclosed
EP-1187615-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. Leuven Research & Development (BE) 2002-03-20 EP disclosed
WO-2000045800-A2 IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236255-A1 Immunosuppressive effects of pteridine derivatives TPMT, FKBP5, RRP15 KDM4E 1278/4885ALDH1A1 1744/4885GAA 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.